Effect of rituximab on human in vivo antibody immune responses. - Wikidata - awgldk - TriplyDB

Effect of rituximab on human in vivo antibody immune responses.

Effect of rituximab on human in vivo antibody immune responses.

http://www.wikidata.org/entity/Q36860483

about

Islet inflammation: a unifying target for diabetes treatment?Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy Immune therapy in type 1 diabetes mellitus Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy.The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.Phage neutralization by sera of patients receiving phage therapy Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes-Prone Mice.Impact of infection or vaccination on pre-existing serological memory Rituximab-treated patients have a poor response to influenza vaccination Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.B Cell in Autoimmune Diseases.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy Prevention of type 1A diabetes mellitus Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy.Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice B-lymphocyte depletion with rituximab and β-cell function: two-year results Advances in basic and clinical immunology in 2011.Progress in immune-based therapies for type 1 diabetes.Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes Targeted immune interventions for type 1 diabetes: not as easy as it looks!B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab Therapy for Childhood Pemphigus Vulgaris.B cell-targeted immunotherapy for type 1 diabetes: What can make it work?Antiphage activity of sera during phage therapy in relation to its outcome.Characterization of the B cell response to Leishmania infection after anti-CD20 B cell depletion.Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota.Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?Meningococcal sepsis complicating eculizumab treatment despite prior vaccination.Plasma cell survival in the absence of B cell memory.

P2860

Q26860847-CF1B4D84-06A1-4D1C-AAC8-15533ED3A8C0 Q28080304-AD217578-128F-4702-B9D0-38FD07BA3270 Q28282846-6054050E-0313-4342-91FE-DCAA066D033C Q30279230-C2B91B4B-FD79-4910-9951-C1015DDCB8C5 Q33409067-EA4026B0-1556-4970-A848-B72121A220F2 Q33568712-379099EF-9F82-47DF-938A-E856948080D3 Q33828266-6664964B-0B6B-41E8-86F2-BB72E0F20099 Q34289040-14FC14BE-6D01-46A8-9D29-125F8E31B2E5 Q35360844-7067389C-650E-4C94-A92F-52950FEA00E0 Q36260514-06360895-F399-44F0-A7A3-911E5129005C Q36339034-84763382-9E91-49C4-BE42-71F210C8AB1B Q36589247-E412AB5D-807D-4CD1-AB5D-2AA426508552 Q36807999-40C7909F-5E82-4955-9C32-A932C66D6172 Q36954468-3BEA4FD8-294A-4960-9C5A-233ED3121AF1 Q37117624-AF168220-63F2-4837-B8BF-39C402825AC9 Q37158249-5D4CD9FE-AFD1-4646-8375-6C9B92BD1054 Q37360042-C55A0C7F-D519-4C67-BAAB-1749AF79129E Q37490637-CFC6E962-D77C-4068-B268-21F582AB4E51 Q37504134-0E8ADA68-EFEB-49E1-90F4-82073E4E25DF Q37972191-B27D7818-5D49-4B2A-9DBD-B7023392C484 Q38097920-6AFF0DB5-40DB-45C2-A854-61778D31DE84 Q38117282-FA7CA9F2-904A-497A-89CB-5E5AF2F65F5C Q38225173-D88E1304-7631-4EDD-9486-309E25FA03C0 Q38371009-86A70C14-3704-4C1F-9F36-B0A3C4CF0ABA Q38696243-23CB8FDB-35E1-41BE-ADF3-4EC0ABB1D68B Q38817783-11E94F36-D47A-4780-B8A0-0A0717C0BD4D Q38819873-A55E7CC2-7360-4F52-9D9A-CCE0136987EA Q41059758-640627D2-20BD-403F-9472-EAD2341413F3 Q41453198-A127630E-6D3B-4E56-A75C-1679BD72E2C0 Q42215038-0AE3C3FB-9CD5-438A-8B46-FFB3A29944AB Q42229459-3A83AA2E-C8A3-43A7-BA20-F70EDB478317 Q42356199-F07C39D6-6751-4374-B1FE-3928EBA5F727 Q44204666-13D5A5DA-3B8A-4542-8134-9EFD8A839EF5 Q47113778-5F328655-813B-4C5D-BDA5-E9F5EACDF345

P2860

Effect of rituximab on human in vivo antibody immune responses.

http://www.wikidata.org/entity/Q36860483

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Effect of rituximab on human in vivo antibody immune responses.

@en

type

label

Effect of rituximab on human in vivo antibody immune responses.

@en

prefLabel

Effect of rituximab on human in vivo antibody immune responses.

@en

P1433

Q36860483-9FE1B5A0-74DE-4EF4-8F07-D734264FA142

P1476

Q36860483-D085E4D4-8570-49A8-A6B0-C89B397CFE9F

P2093

Q36860483-08E88DF0-12DD-476D-BE74-B6A78678A5C5

Q36860483-12E58317-73F5-4FED-B57A-735ED1FAAC2B

Q36860483-513C4391-00C6-48BB-8D03-CFE7E54218AE

Q36860483-54FE735A-871D-44FF-B410-0D95FD5EE592

Q36860483-61F0E870-7DC3-4CC8-8A28-817A80512CF2

Q36860483-746AFDF0-48D9-4509-9E2D-EBE5ECDD7CDE

Q36860483-7DA5F47C-7CCD-4B7B-9980-ED825145B42C

Q36860483-9B25B3D7-4A2F-4B56-BDB5-1ED8162C61E5

Q36860483-B56BDDF5-4902-4089-AC51-EFAED808EFCC

Q36860483-BA458B3A-A8C9-4F82-A95E-59E627BA6A79

P2860

Q36860483-0C8A2302-5499-4DC1-A02F-DAA2CE9EA635

Q36860483-106FAEBB-6628-41A5-B08A-95BE7CD3C28D

Q36860483-175E8A6F-BE69-4870-910D-CAFADA10A93F

Q36860483-21C02158-B864-4E4A-A0FA-1A5BA7F9EFBB

Q36860483-2D3A5CDD-BAFA-4537-9354-2A19453DEA8C

Q36860483-31CBA9FB-1256-4542-B5F9-6BBAF6B45655

Q36860483-38DA63B2-8A6A-47B5-A592-BDDAFA10BD2A

Q36860483-4C13A6A9-FB9B-491E-A1D7-45B032801A2D

Q36860483-4ED7C187-6D73-47B4-ACC7-E96E0E0EF85C

Q36860483-4F0B1718-7CA5-4539-BD49-C57797C90C8B

P304

Q36860483-3AE3D655-3473-44ED-AFEB-E738C22D837D

P31

Q36860483-879A7826-13D7-410F-BA0C-C6E67F97314C

P356

Q36860483-B66CB496-DE4B-4FD7-BDFD-7C9A53B3F8C3

P407

Q36860483-9C420D9B-25EC-42E1-9678-8A9D6F966251

P433

Q36860483-F9822564-B054-4B57-83D0-773922F4D19A

P478

Q36860483-7C1B6D82-03C6-4B29-9C59-618F8A4F9DFD

P50

Q36860483-F72FEF2A-FB1F-4CF5-8708-F571902CEBD4

P577

Q36860483-72A917B4-8E96-4B47-ABAE-CCEB8279241F

P5875

Q36860483-50C14CE5-8032-4653-B982-8741FD6B04F6

P698

Q36860483-9FA24069-DC0A-45F1-B11D-D07FC0B1CD92

P932

Q36860483-8B9C8D6D-7D8D-4341-88BE-7874D485AF70

P356

J.JACI.2011.08.008

P1433

The Journal of Allergy and Clinical Immunology

P1476

Effect of rituximab on human in vivo antibody immune responses.

@en

P2093

Adriana Weinberg

http://www.w3.org/2001/XMLSchema#string

Carla Greenbaum

http://www.w3.org/2001/XMLSchema#string

Elizabeth Ocheltree

http://www.w3.org/2001/XMLSchema#string

Hans D Ochs

http://www.w3.org/2001/XMLSchema#string

Heidi Krause-Steinrauf

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jennifer Canniff

http://www.w3.org/2001/XMLSchema#string

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Mark D Pescovitz

http://www.w3.org/2001/XMLSchema#string

Paula McGee

http://www.w3.org/2001/XMLSchema#string

P2860

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients.

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.

Primary immunodeficiencies. Report of a World Health Organization Committee.

P304

1295-1302.e5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2011.08.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51639489

http://www.w3.org/2001/XMLSchema#string

P698

21908031

http://www.w3.org/2001/XMLSchema#string

P932

3659395

http://www.w3.org/2001/XMLSchema#string